LungLifeAI Logo

Statistical Data about Lung Cancer


Our mission at LungLife is driven from important and compelling statistical data about lung cancer. According to the American Society of Clinical Oncology, Lung cancer is the leading cancer killer in the world. In 2020 alone, almost 1.8 million people died worldwide from lung cancer. To put this number in perspective, 1.8 million people died from Covid in 2020.

1.8 million – That’s exactly the same number that died from lung cancer, yet lung cancer receives a fraction of the attention that has been paid to Covid.

While statistics about death are never pleasant, there is some good news. In the United States, the number of newly-diagnosed lung cancer patients has been dropping each year since the 1980s for men and since the early 2000s for women. These statistics correlate closely with a decline in smoking rates.

While these figures are encouraging, we still have a long way to go. It’s a disheartening fact that the current five-year survival rate for people diagnosed with all types of lung cancer is only 22%.

To break this number down further, here are some numbers that we find fascinating. The estimated five-year survival rate for those diagnosed with stage 1 non-small cell lung cancer is 63%. If the cancer has spread outside the lungs to nearby lymph nodes, the survival rate is 35%, and if it has metastasized to other parts of the body, the survival rate drops to just 7%.

From those numbers, the key inference is that early detection is paramount to long-term survival.

Here’s where we have some exciting news to share. Our company is using artificial intelligence to aid with the early detection of lung cancer. LungLife is developing technology that will pair a simple blood draw with artificial intelligence to provide clinicians and patients the information they need to make informed decisions about the management of lung nodules and lung cancer. Early detection means better care, better outcomes, and longer lives.

We at LungLife strive to be a driving force in the early detection of lung cancer.

For more information about the great work we are doing, visit our website at

Recent Episodes

How Our LungLB®'s Test is Saving Lives
Early Detection
Creating a Different Future
LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.